Companies / RAC

RACURA ONCOLOGY LTD

ASX:RACPharmaceuticals, Biotechnology & Life Sciences
196.1M shares on issueASX (delayed) · as of 28 July 2026$2.07price · delayed$401.9Mmarket cap · indicative
C
Dilution grade

Share count grew 15% in 24 months; 2 cash raises in 24 months; options/rights overhang 6% of shares

Cash runway10.9 quarters of funding
Share-count growth (24m)15.1%
Raise cadence (24m)2 cash raises
Options & rights overhang5.5% of shares
In-the-money supply2.7% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

RACURA ONCOLOGY LTD's ordinary share count grew 15.1% between July 2024 and June 2026, standing at 196M shares as of June 2026. The company raised capital twice in that period for total proceeds of A$4.2M, most recently A$1000K in June 2026. Options and rights on issue could convert into 11M new shares, equal to 5.5% of the current share count, of which 3% are in the money; the nearest expiry is December 2026. At the June 2026 quarter the company reported A$33.3M in cash, equivalent to 10.9 quarters of cover at its reported burn rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
5.5%
Max option dilution
2.7%
ITM option dilution
2
Raises · last 12 months
10.9 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 196.1M per ASX (delayed) (28 July 2026).
178.4M184.9M191.4MDec 24Sept 25July 26Cash raise · 3 June 2026Cash raise · 8 Dec 2025

Cash runway

10.9 qtrs
More than four quarters of funding at the recent spend rate.
$33.3M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
12 July 20263H · cancellationRAC : ORDINARY FULLY PAID196.1MAppendix 3H
1 July 20263H · cancellationRAC : ORDINARY FULLY PAID196.1MAppendix 3H
16 June 20262A · quoted issueRAC : ORDINARY FULLY PAID196.1MAppendix 2A
11 June 20262A · quoted issueRAC : ORDINARY FULLY PAID195.6MAppendix 2A
4 June 20263H · cancellationRAC : ORDINARY FULLY PAID195.0MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

$1000k
Capital raise
3 June 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

5.5%
Total overhang · of current shares
2.7%
In the money · at current price
10.8M
Potential new shares
Dec 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
5 June 2026Dr Sergio ScrofaniBuy11k—$30k3Y notice
28 May 2026Daniel TillettBuy400k—$500k3Y notice
26 May 2026Daniel TillettBuy400k—$500k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026$PJune 2026 Quarterly Activities Report and Appendix 4C
12 July 2026Notification of cessation of securities - RAC
9 July 2026Racura to Present CPACS Data at GCOS 2026
6 July 2026Racura Oncology New Zealand Investor Events
2 July 2026$PBellberry Ethics Approval Activates New HARNESS Trial Sites
1 July 2026Notification of cessation of securities - RAC
24 June 2026$PRacura Treats First Patient in HARNESS-1 Lung Cancer Trial
16 June 2026Racura Oncology Investor Briefings Perth & Auckland
16 June 2026$PRacura raised $34.3m to Advance Three Oncology Trials
16 June 2026Cleansing Notice
16 June 2026Application for quotation of securities - RAC
11 June 2026Cleansing Notice
11 June 2026Application for quotation of securities - RAC
8 June 2026Appendix 3Y-Dr Serge Scrofani
4 June 2026Racura Options Raised $24.4m
4 June 2026Notification of cessation of securities - RAC
3 June 2026Proposed issue of securities - RAC
3 June 2026$PEmerging Companies Specialist Invests in Racura
1 June 2026Application for quotation of securities - RAC
29 May 2026Application for quotation of securities - RAC

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.